ライフサイエンスコーパス: lysophosphatidic acid receptor

1 h the EGFR and a G protein-coupled receptor (lysophosphatidic acid receptor).

2 lity of crosstalk between G2A and endogenous lysophosphatidic acid receptors.

3 ycyclohexyl acid BMS-986278 (33) is a potent lysophosphatidic acid receptor 1 (LPA(1)) antagonist, wi

4 Lysophosphatidic acid receptor 1 (LPA1) plays a critical

5 l characterization of a potent and selective lysophosphatidic acid receptor 1 (LPAR1) antagonist with

6 Lysophosphatidic acid receptor 1 (LPAR1) antagonists sho

7 cells, at least in part, by associating with lysophosphatidic acid receptor 1 (LPAR1), leading to enh

8 iscovery of a neutral, potent, and selective lysophosphatidic acid receptor 1 antagonist for the trea

9 ection of unidirectional flow; inhibition of lysophosphatidic acid receptor 1 restored the flow-depen

10 (-7), beta = 0.16), which is downstream from lysophosphatidic acid receptor 1.

11 due to impaired macropinocytic uptake of the lysophosphatidic acid receptor 1.

12 intercellular gaps, which were abolished by lysophosphatidic acid receptor 1/2 inhibition.

13 cordycepin, the BCL6 inhibitor 79-6, and the lysophosphatidic acid receptor 1/3 inhibitor Ki16425).

14 The involvement of lysophosphatidic acid receptor 2 (LPA(2)) in IPF is supp

15 emonstrate that this activity is mediated by lysophosphatidic acid receptor 3 (Lpar3).

16 Here we report that lysophosphatidic acid receptor 4 (LPAR4) becomes transie

17 ctivation is impaired downstream of both the lysophosphatidic acid receptor, a G-protein-coupled rece

18 nduced activation of pro-apoptotic pathways (lysophosphatidic acid receptor and caspase-domain signal

19 Lysophosphatidic acid receptor antagonists are currently

20 riptionally down-regulates expression of the lysophosphatidic acid receptor EDG2 and this down-regula

21 ution, and genetics of lp(A2)/Edg4, a second lysophosphatidic acid receptor gene, we characterized it

22 Berridge [11] showed that activation of the lysophosphatidic acid receptor in a restricted region of

23 ibited the endogenous thrombin receptors and lysophosphatidic acid receptors in NIH3T3 cells, whereas

24 both GRK2 and G beta1 gamma2, activation of lysophosphatidic acid receptors leads to the rapid and t

25 Inhibition of the type 2 lysophosphatidic acid receptor (LPA(2)) has recently eme

26 gnaling molecule and activates the family of lysophosphatidic acid receptors (LPA(1-6)).

27 The molecular cloning of three high-affinity lysophosphatidic acid receptors, LPA1, LPA2, and LPA3, p

28 Signaling mediated through type I lysophosphatidic acid receptors (LPAR1) has recently eme

29 on of autotaxin activity, and/or blockade of lysophosphatidic acid receptors might represent new trea

30 makes P-REX1 activation by G(q)/G(i)-coupled lysophosphatidic acid receptors more effective.

31 tion of the epidermal growth factor (EGF) or lysophosphatidic acid receptors or by pervanadate-induce

32 actility and force generation by controlling lysophosphatidic acid receptor recycling and preventing

33 n 6 modulates NADPH oxidase 2 activation via lysophosphatidic acid receptor signaling in the pulmonar

34 However, lysophosphatidic acid receptor-stimulated phosphorylatio

35 Piperidine 3 is a potent and selective lysophosphatidic acid receptor subtype 1 receptor (LPAR1

36 ere on the characterization of a third human lysophosphatidic acid receptor subtype, Edg-7, which med

37 her, our data indicate that Edg-7 is a third lysophosphatidic acid receptor that couples predominantl

38 case of the beta(2)-adrenergic receptor and lysophosphatidic acid receptor, these processes can lead

39 The lysophosphatidic acid receptor type 1 (LPA1) is 1 of 6 k

40 e retraction evoked by Galpha12/13-dependent lysophosphatidic acid receptors was augmented in R7BP-ex

41 GPR92 was confirmed to be a lysophosphatidic acid receptor with weaker responses to